Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Huland, Edith ^a   Heinzer, Hans ^a   Mir, Thomas S ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Inhalation therapy; Interferon ; Interleukin 2; Pulmonary metastases; Quality of life; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

ADMINISTRATION, INHALATION; ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; QUALITY OF LIFE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0031415256     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-379.
2. Patel NP, Lavengood RW. Renal-cell carcinoma: natural history and results of treatment. J Urol 1978;119:722.
3. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-262.
4. de Kernion JB. Treatment of advanced renal-cell carcinoma: traditional methods and innovative approaches. J Urol 1983;130:2.
5. Goepel M, Rübben H. Adjuvant therapy in renal cancer. World J Urol 1991;9:232-236.
6. Bubenik J, Perlmann P, Indrova M et al. Growth inhibition of an MC induced mouse sarcoma by TCGF (IL-2)-containing preparations. Preliminary report. Cancer Immunol Immunother 1983; 4:205-206.
7. Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 1986;46:1784-1792.
8. Atzpodien J, Körfer A, Franks CR et al. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990;335:1509-1512.
9. Figlin RA, Belldegrun A, Moldawer N et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2a: an active outpatient regimen in metastatic renal-cell carcinoma. J Clin Oncol 1992;10:414-421.
10. Hänninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastic renal-cell carcinoma: risk and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
11. Hofmockel G, Langer W, Theiss M et al. Immuno-chemo for metastic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996;156:18-21.
12. Lümmen G, Goepel M, Möllhoff S et al. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol 1996;155:455-458.
13. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1997;316:889-897.
14. Sosman JA, Kohler PC, Hank JA et al. Repetitive weekly cycles of interleukin-2: clinical and immunologic effects of dose, schedule, and addition of indomethacin [part 2]. J Natl Cancer Inst 1988; 80:1451-1461.
15. West WH, Tauer KW, Yanelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
16. Lee RE, Lotze MT, Skibber JM et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20.
17. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
18. Rosenstein M, Ettinghausen SE, Rosenberg SA Extravasation of intravascular fluid mediated by systemic administration of recombinant interleukin 2. J Immunol 1986;137:1735-1742.
19. Atzpodien J, Körfer A, Schomburg A et al. Treatment strategies in patients with advanced metastatic renal-cell cancer. Onkologie 1991;14[suppl 3]:11.
20. Dillman RO, Church C, Oldham RK et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience. Cancer 1993;71:2358-2370.
21. Parkinson DR, Abrams JS, Wiernik PH et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8:1650-1656.
22. Rosenberg SA, Lotze MT, Yang JC et al. Experience with die use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
23. Fisher RI, Rosenberg SA, Sznol M et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997;3[suppl 1]:S70-S72.
24. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
25. Huland E, Falk B, Huebner D et al. In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors. J Cancer Res Clin Oncol 1995;121:285-290.
26. Huland E, Huland H. Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989;49:5469-5474.
27. Aulitzky WE, Kessler M, Wilhelm M et al. Aerosolized natural interleukin-2 for treatment of advanced malignancy: results of a phase I trial [abstract]. Ann Hematol 1993;66[suppl 2]:A109.
28. Huland E, Heinzer H, Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 1994;120:221-228.
29. Huland E, Huland H, Heinzer H. Interleukin-2 by inhalation: local therapy for metastatic renal-cell carcinoma. J Urol 1992;147: 344-348.
30. Kaiser U, Pflüger K-H, Havemann K et al. Inhalation therapy with interleukin 2 in bronchio alveolar carcinoma [abstract]. Onkologie 1995;18[suppl 2]:94.
31. Knobloch R. Kombinierte immun-/chemotherapie des fortgeschrittenen nierenzellkarzinoms mit interleukin-2, interferon alpha 2a, und vinblastin. Presented at the 37th Tagung Südwestdeutsche Gesellschaft für Urologie; May 1996; Karlsruhe, Germany.
32. Kelling S, Heinzer H, Huland E et al. In vitro model for nebulizing interleukin-2: quantitative evaluation and biological activity of three different preparations of nebulized IL-2 [abstract]. Immunobiology 1996;196:110-111.
33. Zissel G, Aulitzky WE, Lorenz J et al. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol Immunother 1996;42: 122-126.
34. Marchese E, Vita N, Maureaud T et al. Seperation by cation-exchange high-performance liquid chromatography of three forms of Chinese hamster ovary cell-derived recombinant human interleukin-2. J Chromatogr 1990;504:351-358.
35. Vita N, Magazin M, Marchese E et al. Closely related glycosylation of recombinant human IL-2 expressed in a CHO cell line and natural IL-2. Lymphokine Res 1990;9:67-79.
36. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313.
37. Lissoni P, Barni S, Ardizzoia A et al. Prognostic factors of clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal carcinoma. Oncology 1994; 51:59-62.
38. Mani S, Todd MB, Katz K et al. Prognostic factors of survival in patients with metastatic renal cell cancer treated with biological modifiers. J Urol 1995;154:35-40.
39. Palmer PA, Vinke J, Philip T et al. Prognostic factors of survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480.
40. Belldegrun A, Franklin J, Dorey F et al. Long term survival of 181 patients with metastatic renal cell carcinoma treated with IL-2 based immunotherapy with/without tumor infiltrating lymphocytes [abstract]. J Urol 1996;155:656A